Key cancer cell signal transduction pathways as therapeutic targets

被引:111
作者
Bianco, RB
Melisi, D
Ciardiello, F
Tortora, G
机构
[1] Univ Naples Federico II, Dipartimento Endocrinol & Oncol Mol & Clin, I-80131 Naples, Italy
[2] Seconda Univ Napoli, Dipartimento Medicochirurg Internist Clin & Speri, I-80131 Naples, Italy
关键词
cancer therapy; angiogenesis; EGFR; targeted agents;
D O I
10.1016/j.ejca.2005.07.034
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Growth factor signals are propagated from the cell surface, through the action of transmembrane receptors, to intracellular effectors that control critical functions in human cancer cells, such as differentiation, growth, angiogenesis, and inhibition of cell death and apoptosis. Several kinases are involved in transduction pathways via sequential signalling activation. These kinases include transmembrane receptor kinases (e.g., epidermal growth factor receptor EGFR); or cytoplasmic kinases (e.g., PI3 kinase). in cancer cells, these signalling pathways are often altered and results in a phenotype characterized by uncontrolled growth and increased capability to invade surrounding tissue. Therefore, these crucial transduction molecules represent attractive targets for cancer therapy. This review will current knowledge of key signal transduction pathways, that are altered in cancer cells, as therapeutic targets for novel selective inhibitors. The most advanced targeted agents currently under development interfere with function and expression of several signalling molecules, including the EGFR family; the vascular endothelial growth factor and its receptors; and cytoplasmic kinases such as Ras, PI3K and mTOR. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:290 / 294
页数:5
相关论文
共 30 条
[1]   The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[2]   Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? [J].
Arteaga, CL ;
Baselga, J .
CANCER CELL, 2004, 5 (06) :525-531
[3]   The Akt/PKB family of protein kinases: A review of small molecule inhibitors and progress towards target validation [J].
Barnett, SF ;
Bilodeau, MT ;
Lindsley, CW .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (02) :109-125
[4]   The TOR pathway: A target for cancer therapy [J].
Bjornsti, MA ;
Houghton, PJ .
NATURE REVIEWS CANCER, 2004, 4 (05) :335-348
[5]  
Brognard J, 2001, CANCER RES, V61, P3986
[6]   Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy [J].
Ciardiello, F ;
Bianco, R ;
Caputo, R ;
Caputo, R ;
Damiano, V ;
Troiani, T ;
Melisi, D ;
De Vita, F ;
De Placido, S ;
Bianco, AR ;
Tortora, G .
CLINICAL CANCER RESEARCH, 2004, 10 (02) :784-793
[7]   Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs [J].
Ciardiello, F ;
Tortora, G .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (10) :1348-1354
[8]   Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[9]   Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].
Eberhard, DA ;
Johnson, BE ;
Amler, LC ;
Goddard, AD ;
Heldens, SL ;
Herbst, RS ;
Ince, WL ;
Jänne, PA ;
Januario, T ;
Johnson, DH ;
Klein, P ;
Miller, VA ;
Ostland, MA ;
Ramies, DA ;
Sebisanovic, D ;
Stinson, JA ;
Zhang, YR ;
Seshagiri, S ;
Hillan, KJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909
[10]   The biology of VEGF and its receptors [J].
Ferrara, N ;
Gerber, HP ;
LeCouter, J .
NATURE MEDICINE, 2003, 9 (06) :669-676